Cresset Asset Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.4M | Sell |
104,792
-2,638
| -2% | -$395K | 0.06% | 193 |
|
|
2026
Q1 | $16.4M | Buy |
107,430
+598
| +0.6% | +$91.7K | 0.07% | 183 |
|
|
2025
Q4 | $14.7M | Sell |
106,832
-1,540
| -1% | -$202K | 0.06% | 194 |
|
|
2025
Q3 | $13.9M | Buy |
108,372
+3,420
| +3% | +$417K | 0.06% | 190 |
|
|
2025
Q2 | $12.7M | Sell |
104,952
-8,881
| -8% | -$1M | 0.06% | 185 |
|
|
2025
Q1 | $13.1M | Buy |
113,833
+77,048
| +209% | +$8.2M | 0.07% | 188 |
|
|
2024
Q4 | $3.58M | Sell |
36,785
-41,353
| -53% | -$4.41M | 0.02% | 411 |
|
|
2024
Q3 | $8.99M | Buy |
78,138
+8,452
| +12% | +$959K | 0.03% | 334 |
|
|
2024
Q2 | $7.42M | Buy |
69,686
+9,407
| +16% | +$944K | 0.03% | 350 |
|
|
2024
Q1 | $6.05M | Buy |
60,279
+2,647
| +5% | +$271K | 0.03% | 350 |
|
|
2023
Q4 | $5.82M | Buy |
57,632
+1,870
| +3% | +$181K | 0.03% | 305 |
|
|
2023
Q3 | $5.68M | Buy |
55,762
+2,687
| +5% | +$273K | 0.02% | 302 |
|
|
2023
Q2 | $5.36M | Buy |
53,075
+32,816
| +162% | +$3.28M | 0.01% | 399 |
|
|
2023
Q1 | $1.86M | Buy |
20,259
+167
| +0.8% | +$14.6K | 0.04% | 240 |
|
|
2022
Q4 | $1.81M | Sell |
20,092
-3,448
| -15% | -$290K | 0.02% | 212 |
|
|
2022
Q3 | $1.79M | Sell |
23,540
-119
| -0.5% | -$9.86K | 0.02% | 229 |
|
|
2022
Q2 | $2M | Sell |
23,659
-1,011
| -4% | -$88.7K | 0.02% | 229 |
|
|
2022
Q1 | $2.17M | Buy |
24,670
+712
| +3% | +$61.6K | 0.02% | 234 |
|
|
2021
Q4 | $2.1M | Sell |
23,958
-2,004
| -8% | -$166K | 0.02% | 290 |
|
|
2021
Q3 | $2.12M | Buy |
25,962
+5,478
| +27% | +$493K | 0.03% | 222 |
|
|
2021
Q2 | $1.87M | Sell |
20,484
-7,321
| -26% | -$652K | 0.03% | 214 |
|
|
2021
Q1 | $2.38M | Buy |
27,805
+2,145
| +8% | +$192K | 0.04% | 152 |
|
|
2020
Q4 | $2.42M | Buy |
25,660
+4,107
| +19% | +$359K | 0.04% | 140 |
|
|
2020
Q3 | $1.87M | Sell |
21,553
-4,053
| -16% | -$351K | 0.04% | 174 |
|
|
2020
Q2 | $2.24M | Buy |
25,606
+17,432
| +213% | +$1.5M | 0.05% | 138 |
|
|
2020
Q1 | $674K | Buy |
8,174
+601
| +8% | +$53.6K | 0.02% | 240 |
|
|
2019
Q4 | $717K | Sell |
7,573
-108
| -1% | -$9.69K | 0.02% | 251 |
|
|
2019
Q3 | $667K | Buy |
7,681
+2,999
| +64% | +$269K | 0.02% | 225 |
|
|
2019
Q2 | $428K | Sell |
4,682
-1,575
| -25% | -$133K | 0.01% | 270 |
|
|
2019
Q1 | $539K | Buy |
6,257
+2,681
| +75% | +$215K | 0.02% | 177 |
|
|
2018
Q4 | $275K | Buy |
+3,576
| New | +$278K | 0.02% | 170 |
|
Other funds holding NVS
Cresset Asset Management's NVS Position: Q2 2026 in Review
Cresset Asset Management reduced its Novartis (NVS) stake by 2.5% in Q2 2026, selling an estimated $395K and leaving 104,792 shares worth $16.4M. The position accounts for 0.06% of the portfolio, ranked #193.
Cresset Asset Management first reported a position in NVS in Q4 2018 and has held it in 31 quarters since. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Cresset Asset Management held 104,792 shares of Novartis worth $16.4M as of Q2 2026.
- Cresset Asset Management sold 2,638 Novartis shares in Q2 2026, an estimated $395K.
- Novartis made up 0.06% of Cresset Asset Management's portfolio in Q2 2026, its #193 holding.
- Cresset Asset Management first reported a position in Novartis in Q4 2018 and has held it in 31 quarters since.
- 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.